Literature Review on Health Emigration in Rare Diseases—A Machine Learning Perspective
Author
Abstract
Suggested Citation
Download full text from publisher
References listed on IDEAS
- Kessel, Maura & Hannemann-Weber, Henrike & Kratzer, Jan, 2012. "Innovative work behavior in healthcare: The benefit of operational guidelines in the treatment of rare diseases," Health Policy, Elsevier, vol. 105(2), pages 146-153.
- Nicole B. Simpson, 2022.
"Demographic and economic determinants of migration,"
IZA World of Labor, Institute of Labor Economics (IZA), pages 373-373, July.
- Nicole B. Simpson, 2017. "Demographic and economic determinants of migration," IZA World of Labor, Institute of Labor Economics (IZA), pages 373-373, June.
- Patrizio Armeni & Marianna Cavazza & Entela Xoxi & Domenica Taruscio & Yllka Kodra, 2021. "Reflections on the Importance of Cost of Illness Analysis in Rare Diseases: A Proposal," IJERPH, MDPI, vol. 18(3), pages 1-18, January.
- Michael Drummond & Adrian Towse, 2014. "Orphan drugs policies: a suitable case for treatment," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(4), pages 335-340, May.
- Belousova, Olga A. & Groen, Aard J. & Ouendag, Aniek M., 2020. "Opportunities and barriers for innovation and entrepreneurship in orphan drug development," Technological Forecasting and Social Change, Elsevier, vol. 161(C).
- Gregory S. Zaric, 2008. "Optimal drug pricing, limited use conditions and stratified net benefits for Markov models of disease progression," Health Economics, John Wiley & Sons, Ltd., vol. 17(11), pages 1277-1294, November.
- Lundberg, Ian & Brand, Jennie E. & Jeon, Nanum, 2022. "Researcher reasoning meets computational capacity: Machine learning for social science," SocArXiv s5zc8, Center for Open Science.
- Javier Orofino & Javier Soto & Miguel Casado & Itziar Oyagüez, 2010. "Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007," Applied Health Economics and Health Policy, Springer, vol. 8(5), pages 301-315, September.
- Gregory S. Zaric, 2008. "Optimal drug pricing, limited use conditions and stratified net benefits for Markov models of disease progression," Health Economics, John Wiley & Sons, Ltd., vol. 17(11), pages 1277-1294.
- Elżbieta Szaruga & Elżbieta Załoga, 2022. "Qualitative–Quantitative Warning Modeling of Energy Consumption Processes in Inland Waterway Freight Transport on River Sections for Environmental Management," Energies, MDPI, vol. 15(13), pages 1-21, June.
- Jonathan Cortés-Martín & Lourdes Díaz-Rodríguez & Beatriz Piqueras-Sola & Raquel Rodríguez-Blanque & Antonio Bermejo-Fernández & Juan Carlos Sánchez-García, 2020. "Hajdu–Cheney Syndrome: A Systematic Review of the Literature," IJERPH, MDPI, vol. 17(17), pages 1-18, August.
- Linda Yamoah & Nick Dragojlovic & Alesha Smith & Larry D. Lynd & Carlo A. Marra, 2021. "Evaluating New Zealanders’ Values for Drug Coverage Decision Making: Trade-Offs between Treatments for Rare and Common Conditions," PharmacoEconomics, Springer, vol. 39(1), pages 109-119, January.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Degtiar, Irina, 2017. "A review of international coverage and pricing strategies for personalized medicine and orphan drugs," Health Policy, Elsevier, vol. 121(12), pages 1240-1248.
- Reza Mahjoub & Fredrik Ødegaard & Gregory S. Zaric, 2018. "Evaluation of a pharmaceutical risk‐sharing agreement when patients are screened for the probability of success," Health Economics, John Wiley & Sons, Ltd., vol. 27(1), pages 15-25, January.
- Alan J. Girling & Richard J. Lilford & Terry P. Young, 2012. "Pricing Of Medical Devices Under Coverage Uncertainty—A Modelling Approach," Health Economics, John Wiley & Sons, Ltd., vol. 21(12), pages 1502-1507, December.
- Jeremy D. Goldhaber-Fiebert & Lauren E. Cipriano, 2023. "Pricing Treatments Cost-Effectively when They Have Multiple Indications: Not Just a Simple Threshold Analysis," Medical Decision Making, , vol. 43(7-8), pages 914-929, October.
- Puig-Junoy, Jaume & López-Valcárcel, Beatriz González, 2014. "Launch prices for new pharmaceuticals in the heavily regulated and subsidized Spanish market, 1995–2007," Health Policy, Elsevier, vol. 116(2), pages 170-181.
- António Afonso & José Alves & Krzysztof Beck, 2022.
"Pay and unemployment determinants of migration flows in the European Union,"
Working Papers REM
2022/0251, ISEG - Lisbon School of Economics and Management, REM, Universidade de Lisboa.
- António Afonso & José Alves & Krzysztof Beck, 2022. "Pay and Unemployment Determinants of Migration Flows in the European Union," CESifo Working Paper Series 10131, CESifo.
- Eline Picavet & Marc Dooms & David Cassiman & Steven Simoens, 2011. "Drugs for rare diseases: Influence of orphan designation status on price," Applied Health Economics and Health Policy, Springer, vol. 9(4), pages 275-279, July.
- Serdar Öztürk & Buket Altınöz, 2022. "An Investigation of the Impact of Health Expenditures on International Migration as a Pull Factor in OECD Countries Using a Panel Vector Autoregression (PVAR) Approach," Journal of Economic Policy Researches, Istanbul University, Faculty of Economics, vol. 9(1), pages 39-52, January.
- Sidra Salam & Aslan Amat Senin, 2022. "A Bibliometric Study on Innovative Behavior Literature (1961–2019)," SAGE Open, , vol. 12(3), pages 21582440221, July.
- Kleinhout-Vliek, Tineke & de Bont, Antoinette & Boer, Bert, 2017. "The bare necessities? A realist review of necessity argumentations used in health care coverage decisions," Health Policy, Elsevier, vol. 121(7), pages 731-744.
- J.-Matthias Schulenburg & Martin Frank, 2015. "Rare is frequent and frequent is costly: rare diseases as a challenge for health care systems," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(2), pages 113-118, March.
- Zuzanna Kłos-Adamkiewicz & Elżbieta Szaruga & Agnieszka Gozdek & Magdalena Kogut-Jaworska, 2023. "Links between the Energy Intensity of Public Urban Transport, Regional Economic Growth and Urbanisation: The Case of Poland," Energies, MDPI, vol. 16(9), pages 1-25, April.
- Inese Mavlutova & Dzintra Atstaja & Janis Grasis & Jekaterina Kuzmina & Inga Uvarova & Dagnija Roga, 2023. "Urban Transportation Concept and Sustainable Urban Mobility in Smart Cities: A Review," Energies, MDPI, vol. 16(8), pages 1-16, April.
- Nicod, Elena & Annemans, Lieven & Bucsics, Anna & Lee, Anne & Upadhyaya, Sheela & Facey, Karen, 2019. "HTA programme response to the challenges of dealing with orphan medicinal products: Process evaluation in selected European countries," Health Policy, Elsevier, vol. 123(2), pages 140-151.
- Elżbieta Szaruga & Elżbieta Załoga, 2022. "Environmental Management from the Point of View of the Energy Intensity of Road Freight Transport and Shocks," IJERPH, MDPI, vol. 19(21), pages 1-22, November.
- Witsarut Achariyaviriya & Wongkot Wongsapai & Kittitat Janpoom & Tossapon Katongtung & Yuttana Mona & Nakorn Tippayawong & Pana Suttakul, 2023. "Estimating Energy Consumption of Battery Electric Vehicles Using Vehicle Sensor Data and Machine Learning Approaches," Energies, MDPI, vol. 16(17), pages 1-14, September.
- Oudom Hean, 2022. "The Effects of Technological Progress in Innovative Regions on the Labor Markets of Lagging Regions: A Theoretical Perspective," Economies, MDPI, vol. 10(8), pages 1-12, August.
- Crippa, Andrea & d'Agostino, Giorgio & Dunne, Paul & Pieroni, Luca, 2022. "Conflict as a Cause of Migration," MPRA Paper 112327, University Library of Munich, Germany.
- Marek Piotrowski & Paweł Huras & Katarzyna Modrzejewska, 2021. "Determinants of the human capital redistribution. What pushes out and what pulls to the regions of Masovian Voivodship," Entrepreneurship and Sustainability Issues, VsI Entrepreneurship and Sustainability Center, vol. 9(2), pages 50-64, December.
- Leonardo Salvatore Alaimo & Francesco Amato & Filomena Maggino & Alfonso Piscitelli & Emiliano Seri, 2023. "A Comparison of Migrant Integration Policies via Mixture of Matrix-Normals," Social Indicators Research: An International and Interdisciplinary Journal for Quality-of-Life Measurement, Springer, vol. 165(2), pages 473-494, January.
More about this item
Keywords
health emigration; rare disease; orphan drug; access gap; discrimination in access to therapy;All these keywords.
Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:20:y:2023:i:3:p:2483-:d:1051758. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.